AI-generated from publicly available materials.The Therapeutic Goods Administration (TGA) has identified that eight out of twelve AI-powered digital scribes may require regulation as medical devices, despite suppliers not classifying them as such.
This review, published on October 16, underscores a significant gap in the awareness of medical device regulations among suppliers as AI scribes evolve from simple documentation tools to systems that can influence patient care through recommendations. The TGA has issued guidance to clarify the regulatory landscape for these technologies and intends to implement focused compliance measures based on associated risks.
In its analysis, the TGA surveyed around 100 digital scribe suppliers in Australia, receiving 40 responses and selecting twelve products for deeper evaluation. While eight of these products were deemed likely to meet the medical device criteria, the remaining four required further investigation. Notably, the review included well-known entities like Microsoft and Carepatron, although specific product names were not disclosed. The findings revealed that many suppliers lacked a comprehensive understanding of the regulations, with some mistakenly asserting that their products were not medical devices.
The implications of these findings are significant as digital scribes increasingly leverage generative AI to analyze patient data and produce outputs that could affect clinical decisions. The TGA emphasized that products generating patient-specific recommendations may fall under medical device regulations, raising concerns about the reliability of AI-generated outputs and the clinicians' ability to validate these recommendations. The TGA's proactive approach aims to safeguard patient safety while facilitating the integration of beneficial technologies into clinical practice.